(Q38203096)

30 August 2017

High-density lipoproteins in the prevention of cardiovascular disease: changing the paradigm (English)

1 reference

30 August 2017

1 reference

cardiovascular disease

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24713591%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

author name string

D J Rader

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24713591%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

language of work or name

English

0 references

publication date

8 April 2014

1 reference

Clinical Pharmacology & Therapeutics

30 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24713591%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

volume

96

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24713591%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24713591%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

page(s)

48-56

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24713591%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/clpt.2014.79

13 June 2020

exact match

0 references

cites work

Heart disease and stroke statistics--2014 update: a report from the American Heart Association

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Residual macrovascular risk in 2013: what have we learned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Major lipids, apolipoproteins, and risk of vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Effects of torcetrapib in patients at high risk for coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Effects of dalcetrapib in patients with a recent acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Cardioprotective functions of HDLs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Molecular regulation of HDL metabolism and function: implications for novel therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Future therapeutic directions in reverse cholesterol transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

High density lipoprotein: it's not just about lipid transport anymore

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Dense genotyping of candidate gene loci identifies variants associated with high-density lipoprotein cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Genetics of HDL-C: a causal link to atherosclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Biological, clinical and population relevance of 95 loci for blood lipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Discovery and refinement of loci associated with lipid levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Mendelian randomization: prospects, potentials, and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Common variants associated with plasma triglycerides and risk for coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Lipoprotein(a) as a cardiovascular risk factor: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Recent advances in niacin and lipid metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Niacin inhibits surface expression of ATP synthase beta chain in HepG2 cells: implications for raising HDL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Niacin, an old drug with a new twist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with sta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Extended-release niacin or ezetimibe and carotid intima-media thickness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Biochemical characterization of cholesteryl ester transfer protein inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Safety and tolerability of dalcetrapib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Relationship between atorvastatin dose and the harm caused by torcetrapib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Torcetrapib impairs endothelial function in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Effect of torcetrapib on the progression of coronary atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosc

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Safety of anacetrapib in patients with or at high risk for coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Pioglitazone increases apolipoprotein A-I production by directly enhancing PPRE-dependent transcription in HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

The addition of niacin to statin therapy improves high-density lipoprotein cholesterol levels but not metrics of functionality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

7 January 2021

The not-so-simple HDL story: Is it time to revise the HDL cholesterol hypothesis?

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

7 January 2021

Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

7 January 2021

The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

7 January 2021

Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.79

7 January 2021